These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 37039902)
1. A prognostic and immunological analysis of 7B-containing Kelch structural domain (KLHDC7B) in pan-cancer: a potential target for immunotherapy and survival. Ding J; Ji X; Liu L; Chen DZ; Luo N; Yu XT; Guo F J Cancer Res Clin Oncol; 2023 Aug; 149(10):7857-7876. PubMed ID: 37039902 [TBL] [Abstract][Full Text] [Related]
2. A Pan-Cancer Analysis Revealing the Dual Roles of Lysine (K)-Specific Demethylase 6B in Tumorigenesis and Immunity. Ding JT; Yu XT; He JH; Chen DZ; Guo F Front Genet; 2022; 13():912003. PubMed ID: 35783266 [No Abstract] [Full Text] [Related]
3. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer]. Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766 [No Abstract] [Full Text] [Related]
4. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer. Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444 [TBL] [Abstract][Full Text] [Related]
5. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers. Wang N; Zhu L; Wang L; Shen Z; Huang X Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736 [TBL] [Abstract][Full Text] [Related]
6. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures. Zhang X; Wang Y; A G; Qu C; Chen J Front Immunol; 2021; 12():721030. PubMed ID: 34531868 [TBL] [Abstract][Full Text] [Related]
7. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker. Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W Front Immunol; 2021; 12():646523. PubMed ID: 33679809 [TBL] [Abstract][Full Text] [Related]
8. Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy. Jia Y; Guo B; Zhang W; Wang F; Zhang Y; Zhang Q; Li E Front Oncol; 2023; 13():1110207. PubMed ID: 37427102 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of Glutamate-Rich WD Repeat-Containing Protein 1 and Its Potential Clinical Significance for Pancancer. Wu Y; Wu X; Li Y; Zhao W; Yue Y; Wu B; Liu J; Chen X; Shen A Biomed Res Int; 2021; 2021():8201377. PubMed ID: 34616846 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2. Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y Front Immunol; 2023; 14():1155182. PubMed ID: 37275857 [TBL] [Abstract][Full Text] [Related]
11. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer. Wu J; Yu X; Zhu H; Chen P; Liu T; Yin R; Qiang Y; Xu L Front Mol Biosci; 2023; 10():1178446. PubMed ID: 37388242 [No Abstract] [Full Text] [Related]
13. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data. Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720 [TBL] [Abstract][Full Text] [Related]
14. Pan-Cancer Study of SHC-Adaptor Protein 1 (SHC1) as a Diagnostic, Prognostic and Immunological Biomarker in Human Cancer. Chen J; Gao G; Li L; Ding J; Chen X; Lei J; Long H; Wu L; Long X; He L; Shen Y; Yang J; Lu Y; Sun Y Front Genet; 2022; 13():817118. PubMed ID: 35601500 [No Abstract] [Full Text] [Related]
15. A pan-cancer analysis to determine the prognostic analysis and immune infiltration of HSPA5. Zhu RK; Zhang W; Zhang YX; Hui Z; Wang XW Curr Cancer Drug Targets; 2023 May; ():. PubMed ID: 37157205 [TBL] [Abstract][Full Text] [Related]
16. Multi-omics analysis of TLCD1 as a promising biomarker in pan-cancer. Wang S; Zhang M; Sun H; Li T; Hao J; Fang M; Dong J; Xu H Front Cell Dev Biol; 2023; 11():1305906. PubMed ID: 38559424 [No Abstract] [Full Text] [Related]
17. Comprehensive Analysis of Liu J; Zhu B; Chen J; Cao Y Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558 [TBL] [Abstract][Full Text] [Related]
18. Characterization of SHCBP1 to prognosis and immunological landscape in pan-cancer: novel insights to biomarker and therapeutic targets. Jiang F; Shi Y; Wang Y; Ge C; Zhu J; Fang H; Zhang Y; Zhang Y; Jian H; Lei T; Lan S; Cao L; Yu H; Fang D Aging (Albany NY); 2023 Mar; 15(6):2066-2081. PubMed ID: 36920183 [TBL] [Abstract][Full Text] [Related]
19. PRKCSH serves as a potential immunological and prognostic biomarker in pan-cancer. Wang Q; Wang X; Li J; Yin T; Wang Y; Cheng L Sci Rep; 2024 Jan; 14(1):1778. PubMed ID: 38245572 [TBL] [Abstract][Full Text] [Related]
20. FAIM2 is a potential pan-cancer biomarker for prognosis and immune infiltration. Cai J; Ye Z; Hu Y; Wang Y; Ye L; Gao L; Sun Q; Tong S; Sun Z; Yang J; Chen Q Front Oncol; 2022; 12():998336. PubMed ID: 36185230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]